Sort
326,823 grants matching “clinical trial”
Vendor Audit Support Through the Comprehensive and Rapid Response to NIAID Research Programs (CARRRP) Contract
$3,850,000Ted Wright · Icon Government And Public Health Solutions, Inc. · N01 · FY2024 · AI
CLINICAL TRIALS AND INFORMATION MANAGEMENT SUPPORT
$3,849,860Claudine Valmonte · The Emmes Company, Llc · N02 · FY2020 · CA
Vaccine and Treatment Evaluation Unit at Saint Louis University
$3,849,776Daniel F. Hoft · Saint Louis University · UM1 · FY2021 · AI
Data Coordination Center for the RMN
$3,849,502Heping Zhang · Yale University · U10 · FY2009 · HD
CHILDHOOD CANCER SURVIVOR STUDY: Somatic and Germline Sequencing
$3,847,289Gregory Armstrong · St. Jude Children'S Research Hospital · U24 · FY2022 · CA
Messenger RNA Immunogens for initiation of protective HIV non-neutralizing antibodies
$3,846,345Barton F Haynes · Duke University · U19 · FY2021 · AI
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS
$3,846,025Eric S. Orwoll · Oregon Health & Science University · UL1 · FY2009 · RR
Messenger RNA Immunogens for initiation of protective HIV non-neutralizing antibodies
$3,846,023Barton F Haynes · Duke University · U19 · FY2024 · AI
Office of the Clinical Director
$3,844,547Maryland Pao · National Institute Of Mental Health · ZID · FY2015 · MH
Project 3: Peribunyaviridae Pathogenesis and Vaccine Testing
$3,842,980Shannon Ronca · University Of California-Irvine · U19 · FY2024 · AI
MPD Research Consortium
$3,842,401Ronald Hoffman · Icahn School Of Medicine At Mount Sinai · P01 · FY2013 · CA
Back Pain Consortium (BACPAC) Research Program Data Integration, Algorithm Development and Operations Management Center
$3,841,208Kevin J Anstrom · Univ Of North Carolina Chapel Hill · U24 · FY2024 · AR
Metals in the Trial to Assess Chelation Therapy 2 (TACT2M)
$3,840,976Gervasio A Lamas · Mount Sinai Medical Center (Miami Beach) · R01 · FY2018 · AT
NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial in patients with retinitis pigmentosa
$3,839,889Xiangrong Kong · Johns Hopkins University · UG1 · FY2022 · EY
DART2.0: comprehensive cell type-specific behavioral neuropharmacology
$3,838,425Michael R Tadross · Duke University · RF1 · FY2018 · MH
Strategies for Cancer Immunotherapy Development: Preclinical Studies
$3,837,391Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
HIV VACCINE TRIALS NETWORK LEADERSHIP GROUP
$3,837,008Fred Hutchinson Cancer Research Center · U01 · FY2000 · AI
SSCOR in Pediatric Heart Development and Disease
$3,836,294Jane W. Newburger · Boston Children'S Hospital · P50 · FY2008 · HL
Data Coordination Center for the RMN
$3,835,949Heping Zhang · Yale University · U10 · FY2010 · HD
NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Required)
$3,835,883Judith O Hopkins · Southeast Clinical Oncol Res Consortium · UG1 · FY2020 · CA
Informatics for Integrating Biology & the Bedside (i2b2)
$3,835,772Isaac S. Kohane · Brigham And Women'S Hospital · U54 · FY2011 · LM
LcrV Plague Vaccine with Altered Immune Modulatory Properties
$3,835,703Olaf Schneewind · University Of Chicago · U01 · FY2008 · AI
Rebuilding Immunity for Survival
$3,835,265Lee Marshall Nadler · Dana-Farber Cancer Inst · U19 · FY2006 · CA
Colorectal Chemoprevention with Calcium and Vitamin D
$3,834,906John Anthony Baron · Dartmouth College · R01 · FY2006 · CA
Combination Therapy in Multiple Sclerosis
$3,834,565Mount Sinai School Of Medicine Of Nyu · U01 · FY2005 · NS